Pfizer Partners with China Resources for Operations of Four Oncology Drugs in China!
On November 26, 2024, Pfizer announced a strategic cooperation with China Resources Pharmaceutical Commercial to manage the commercialization of four oncology treatments in China. These medications include Anastrozole, Abiraterone, Palbociclib, and Crizotinib, which will be managed by China Resources. Pfizer’s China President, Peng Zhenke, and China Resources’ Deputy General Manager, Han Yuewei, attended the signing ceremony. Among these drugs, Icotinib and Epirubicin have already been included in the alliance procurement list, while Palbociclib and Crizotinib are subject to national negotiations, resulting in significant price reductions. Palbociclib also appeared in the newly published tenth national procurement list, indicating further price cuts. The collaboration will commence on December 1, with Pfizer working closely with China Resources to ensure a smooth transition for affected employees.
2026-10-29
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
IMCD Opens Beauty and Personal Care Lab in California
-
As Middle East Supply Faces Disruptions, SABIC's 1.8 Million Mt/Year Methanol New Project Secures Saudi Feedstock Quota
-
South Korea Moves Urgently to Control Petrochemical Feedstock Hoarding as Supply Chain Risk Escalates to the National Security Level
-
“Shutdown Equals Price Hike”: TDI Market Enters a New Era of “Scarcity Games”
-
Haldia Petrochemicals Pipeline Fire in India Adds Uncertainty to Asia's Naphtha Market
-
Sinochem International Acquires Nantong Xingchen for 2.11 Billion Yuan, Rike Chemical Plans Genyuan New Materials Acquisition – The Changing Landscape of Chemical M&A
-
CordenPharma Invests €80 Million to Raise Sterile Injectable Capacity to 500 Million Units Annually
-
AkzoNobel Reports €388 Million Q3 Adjusted EBITDA as Margins Improve for Sixth Straight Quarter
-
ZPC Plans 1.2 Million-Tonne PDH Unit, Setting a New Global Licensing Record
-
Starboard Discloses Stake in Solstice, Calls for $100 Million in Cost Cuts
Recommend Reading
-
Another Strategic Move! DuPont Launches a New Specialty Lubricants Project in Zhangjiagang
-
Eurofragance Opens New Creative Center in Jakarta to Expand Its Asian Footprint
-
Merck Establishes New Semiconductor Hub in Taiwan
-
“Falling Revenue, Soaring Profits”: Is AkzoNobel’s Financial Alchemy Real Muscle—or Just Smoke and Mirrors?
-
Givaudan to Build New Fragrance Compounding Facility in Pedro Escobedo, Mexico
-
Polyester Bottle Chip Spot Price Rises on the 14th
-
Business Society October 8, 2026 Methanol Trend Analysis: Volatile Consolidation
-
Supply remains generally loose, the acrylonitrile market fluctuates within a range
-
Business Society September 22, 2026 MTBE Trend Analysis: Strong Rebound
-
Business Society October 8, 2026 Acrylic Acid Trend Analysis: Volatile Trend